TY - JOUR
T1 - Advances in PET Imaging of the CXCR4 Receptor
T2 - [68Ga]Ga-PentixaFor
AU - Lindenberg, Liza
AU - Ahlman, Mark
AU - Lin, Frank
AU - Mena, Esther
AU - Choyke, Peter
N1 - Publisher Copyright:
© 2023
PY - 2024/1
Y1 - 2024/1
N2 - [68Ga]Ga-PentixaFor, a PET agent targeting CXCR4 is emerging as a versatile radiotracer with promising applications in oncology, cardiology and inflammatory disease. Preclinical work in various cancer cell lines have demonstrated high specificity and selectivity. In human investigations of several tumors, the most promising applications may be in multiple myeloma, certain lymphomas and myeloproliferative neoplasms. In the nononcologic setting, [68Ga]Ga-PentixaFor could greatly improve detection for primary aldosteronism and other endocrine abnormalities. Similarly, atherosclerotic disease and other inflammatory conditions could also benefit from enhanced identification by CXCR4 targeting. Rapidly cleared from the body with a favorable imaging and radiation dosimetry profile that has been already studied in over 1000 patients, [68Ga]Ga-PentixaFor is a worthy agent for further clinical exploration with potential for theranostic applications in hematologic malignancies.
AB - [68Ga]Ga-PentixaFor, a PET agent targeting CXCR4 is emerging as a versatile radiotracer with promising applications in oncology, cardiology and inflammatory disease. Preclinical work in various cancer cell lines have demonstrated high specificity and selectivity. In human investigations of several tumors, the most promising applications may be in multiple myeloma, certain lymphomas and myeloproliferative neoplasms. In the nononcologic setting, [68Ga]Ga-PentixaFor could greatly improve detection for primary aldosteronism and other endocrine abnormalities. Similarly, atherosclerotic disease and other inflammatory conditions could also benefit from enhanced identification by CXCR4 targeting. Rapidly cleared from the body with a favorable imaging and radiation dosimetry profile that has been already studied in over 1000 patients, [68Ga]Ga-PentixaFor is a worthy agent for further clinical exploration with potential for theranostic applications in hematologic malignancies.
UR - http://www.scopus.com/inward/record.url?scp=85175550918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175550918&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2023.09.002
DO - 10.1053/j.semnuclmed.2023.09.002
M3 - Review article
C2 - 37923671
AN - SCOPUS:85175550918
SN - 0001-2998
VL - 54
SP - 163
EP - 170
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 1
ER -